GIP receptor antagonist and GLP-1 receptor agonist
Maridebart cafraglutide 420 mg injection every 4 weeks
MARI_SC_420MG_Q4W
Effects across outcomes
Bayesian random effects estimate against the comparator of each analysis (usually placebo), posterior median and 95% credible interval. Green: clearly better; red: clearly worse.
| Condition | Outcome | Window | Versus | Effect (95% CrI) | SUCRA |
|---|---|---|---|---|---|
| Overweight or obesity without diabetes (adults) | Serious adverse events | longest follow-up | Placebo | HR 0.70 (0.01 to 53.06) | 0.57 |
| Overweight or obesity without diabetes (adults) | Discontinuation due to adverse events | longest follow-up | Placebo | HR 0.66 (0.01 to 49.25) | 0.65 |
| Overweight or obesity without diabetes (adults) | Nausea | longest follow-up | Placebo | HR 34.40 (4.86 to 844) | 0.04 |
| Overweight or obesity without diabetes (adults) | Vomiting | longest follow-up | Placebo | HR 11.05 (2.19 to 77.73) | 0.22 |
| Overweight or obesity without diabetes (adults) | Diarrhea | longest follow-up | Placebo | HR 4.54 (0.43 to 58.78) | 0.28 |
| Overweight or obesity without diabetes (adults) | Constipation | longest follow-up | Placebo | HR 0.30 (0.00 to 9.56) | 0.80 |